l-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials
Authors:
- George I. PapakostasGPGeorge I. Papakostas
- Richard C. SheltonRSRichard C. Shelton
- John M. ZajeckaJZJohn M. Zajecka
- Bijan EtemadBEBijan Etemad
- Karl RickelsKRKarl Rickels
- Alisabet ClainACAlisabet Clain
- Lee BaerLBLee Baer
- Elizabeth D. DaltonEDElizabeth D. Dalton
- Garret R. SaccoGSGarret R. Sacco
- David SchoenfeldDSDavid Schoenfeld
- Michael PencinaMPMichael Pencina
- Allison MeisnerAMAllison Meisner
- 1 December 2012
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 169 (12) , 1267-1274
Abstract
Patients with major depression who have an insufficient response to selective serotonin reuptake inhibitors (SSRIs) may benefit from the addition of 15 mg/day of l-methylfolate, the only form of folate that crosses the blood-brain barrier. Adding 7.5 mg/day was no more effective than adding placebo, but 15.0 mg/day plus ongoing SSRI treatment produced a 32% response rate, compared to 15% for augmentation with placebo. Side effects in the two groups were comparable in type and frequency. ObjectiveThe authors conducted two multicenter sequential parallel comparison design trials to investigate the effect of l-methylfolate augmentation in the treatment of major depressive disorder in patients who had a partial response or no response to selective serotonin reuptake inhibitors (SSRIs).MethodIn the first trial, 148 outpatients with SSRI-resistant major depressive disorder were enrolled in a 60-day study divided into two 30-day periods. Patients were randomly assigned, in a 2:3:3 ratio, to receive l-methylfolate for 60 days (7.5 mg/day for 30 days followed by 15 mg/day for 30 days), placebo for 30 days followed by l-methylfolate (7.5 mg/day) for 30 days, or placebo for 60 days. SSRI dosages were kept constant throughout the study. In the second trial, with 75 patients, the design was identical to the first, except that the l-methylfolate dosage was 15 mg/day during both 30-day periods.ResultsIn the first trial, no significant difference was observed in outcomes between the treatment groups. In...Keywords
This publication has 33 references indexed in Scilit:
- Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trialsContemporary Clinical Trials, 2011
- Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II)Psychiatry Research: Neuroimaging, 2005
- The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluationPsychological Medicine, 2004
- Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trialJournal of Affective Disorders, 2000
- 5-Methyltetrahydrofolate level in the serum of depressed subjects and its relationship to the outcome of ECTJournal of Affective Disorders, 1994
- Change in folate status with antidepressant treatmentPsychiatry Research, 1994
- Folate deficiency, biopterin and monoamine metabolism in depressionPsychological Medicine, 1992
- Enhancement of recovery from psychiatric illness by methylfolateThe Lancet, 1990
- Folic acid enhances lithium prophylaxisJournal of Affective Disorders, 1986
- Folic acid deficiency and depressionPsychosomatics, 1980